FDA Tells Cedax Maker To Fix Deceptive Marketing

Law360, New York (November 25, 2008, 12:00 AM EST) -- The marketing for Shionogi & Co. Ltd.’s antibiotic Cedax misleads the public by downplaying the drug’s risks and overstretching efficacy claims, the U.S. Food and Drug Administration said in a warning letter to the company on Nov. 14.

The FDA sent a letter ordering Shionogi USA Inc. CEO Sapan A. Shah to update the company's promotional materials to provide more accurate drug claims.

“These violations are concerning from a public health perspective because they suggest that the product is both safer and effective in a broader...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.